Breaking News Instant updates and real-time market news.

ASNA

Ascena Retail

$4.02

-0.21 (-4.96%)

, BAS

Basic Energy

$9.44

0.18 (1.94%)

18:56
09/24/18
09/24
18:56
09/24/18
18:56

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Ascena Retail (ASNA) up 13.2%. ALSO HIGHER: Basic Energy Services (BAS) up 6.0% after all-stock merger proposal from Key Energy (KEG)... Pluristem Therapeutics (PSTI) up 3.8% after FDA orphan designation for its treatment of graft failure... Arena Pharma (ARNA) up 2.9% after positive Phase 2a results for olorinab... Novan (NOVN) up 2.55 after disclosing FDA guidance for SB204. LOWER: Syndax Pharma (SNDX) down 17.0% after update on ENCORE 601 trial... Deciphera (DCPH) down 5.1% after being initiated at Underperform at Leerink... BJ's Wholesale (BJ) down 3.5% after equity offering... PetIQ (PETQ) down 3.3% after equity offering... CenterPoint (CNP) down 3.0% after equity offering... CenturyLink (CTL) down 2.2% after CFO resignation... Petrobras (PBR) down 2.1% after sequential output decline in August.

ASNA

Ascena Retail

$4.02

-0.21 (-4.96%)

BAS

Basic Energy

$9.44

0.18 (1.94%)

KEG

Key Energy

$13.46

-0.18 (-1.32%)

PSTI

Pluristem

$1.31

(0.00%)

ARNA

Arena Pharmaceuticals

$42.80

-1.05 (-2.39%)

NOVN

Novan

$2.72

0.015 (0.56%)

SNDX

Syndax

$7.23

0.46 (6.79%)

DCPH

Deciphera

$39.80

0.78 (2.00%)

BJ

BJ's Wholesale

$28.47

-0.68 (-2.33%)

PETQ

PetIQ

$41.07

-0.55 (-1.32%)

CNP

CenterPoint Energy

$27.81

-0.23 (-0.82%)

CTL

CenturyLink

$22.90

-0.04 (-0.17%)

PBR

Petrobras

$11.40

-0.105 (-0.91%)

  • 24

    Sep

  • 24

    Sep

  • 01

    Oct

  • 02

    Oct

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 28

    Oct

  • 08

    Nov

  • 27

    Nov

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

ASNA Ascena Retail
$4.02

-0.21 (-4.96%)

06/05/18
RILY
06/05/18
NO CHANGE
Target $3.5
RILY
Neutral
Ascena Retail price target raised to $3.50 from $2.50 at B. Riley FBR
B. Riley FBR analyst Susan Anderson raised her price target for Ascena Retail Group to $3.50 saying same-store-sales improvement drove earnings to the high end of guidance in Q3. The analyst keeps a Neutral rating on the shares.
BAS Basic Energy
$9.44

0.18 (1.94%)

12/20/17
GHSC
12/20/17
UPGRADE
GHSC
Buy
Basic Energy upgraded to Buy from Neutral at Seaport Global
01/10/18
01/10/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Helmerich & Payme (HP), Nabors (NBR), RPC, Inc (RES), Basic Energy (BAS) and Superior Energy (SUP) initiated with an Equal Weight at Stephens. The firm also initiated ProPetro (PUMP), Keane (FRAC) and Patterson-UTI (PTEN) with an Overweight. 2. Molson Coors (TAP) and Constellation Brands (STZ) initiated with an Overweight at Barclays, while Brown-Forman (BFA, BFB, BF.A, BF.B) was initiated with an Equal Weight. 3. Cisco (CSCO) assumed with an Overweight at Piper Jaffray, while F5 Networks (FFIV) and Juniper (JNPR) were assumed with a Neutral. 4. CorSite Realty (COR) initiated with an overweight at MUFG. 5. Epizyme (EPZM) initiated with an Overweight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/09/18
SPHN
01/09/18
INITIATION
Target $26
SPHN
Equal Weight
Basic Energy initiated with an Equal Weight at Stephens
Stephens analyst Tommy Moll initiated Basic Energy with an Equal Weight and $26 price target.
05/07/18
PIPR
05/07/18
UPGRADE
Target $17.5
PIPR
Overweight
Basic Energy upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst John Daniel upgraded Basic Energy Services to Overweight while lowering his price target for the shares to $17.50 from $19. The analyst thinks the company's "debt-laden" balance sheet, while responsible for the underperformance of the shares, "falls short of being toxic." He calls Basic Energy a "pleasant anomaly" in the Oilfield Services space given its attractive valuation relative to peers.
KEG Key Energy
$13.46

-0.18 (-1.32%)

12/20/17
GHSC
12/20/17
UPGRADE
GHSC
Buy
Key Energy upgraded to Buy from Neutral at Seaport Global
03/16/18
03/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Atara Biotherapeutics (ATRA) initiated with a Neutral at Guggenheim. 2. Zagg (ZAGG) initiated with a Buy at DA Davidson. 3. Key Energy (KEG) initiated with a Hold at Deutsche Bank. 4. Logitech (LOGI) initiated with a Buy at DA Davidson. 5. Adaptimmune (ADAP) assumed with an Outperform at Leerink. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/16/18
DBAB
03/16/18
INITIATION
Target $17
DBAB
Hold
Key Energy initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Jason Bandel started Key Energy Services with a Hold rating and $17 price target. Fundamentals are improving in production services for the first time in several years, and Key Energy is well positioned to drive both revenue and EBITDA growth in 2018, the analyst contends. He believes, however, that the "challenge is figuring out what the true well servicing rig supply picture is."
PSTI Pluristem
$1.31

(0.00%)

10/06/17
GHSC
10/06/17
INITIATION
Target $5
GHSC
Buy
Pluristem initiated with a Buy at Seaport Global
Seaport Global analyst Vernon Bernardino initiated Pluristem with a Buy and $5 price target.
07/31/18
RILY
07/31/18
INITIATION
Target $4.5
RILY
Buy
Pluristem initiated with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico started Pluristem Therapeutics with a Buy rating and $4.50 price target. The company's two cell therapy product candidates could change the standard of care for unmet medical needs, Zavoico tells investors in a research note.
ARNA Arena Pharmaceuticals
$42.80

-1.05 (-2.39%)

03/20/18
03/20/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Universal Display (OLED) upgraded to Buy from Hold at Gabelli with analyst Hendi Susanto saying he views the negative market response to a Bloomberg report that Apple (AAPL) is designing and producing MicroLED display prototypes as an overreaction and a buying opportunity. 2. Oneok (OKE) upgraded to Buy from Hold at Jefferies with analyst Christopher Sighinolfi saying he is confident in Oneok's ability to hit target returns on $4.2B of its current projects following a recent meeting with management. 3. PPG (PPG) upgraded to Buy from Hold at Deutsche Bank with analyst David Begleiter saying he believes the company's capital deployment and "valuation discount" are attractive. 4. Roku (ROKU) upgraded to Perform from Underperform at Oppenheimer with analyst Jason Helfstein upgraded Roku (ROKU) to Perform citing valuation and the company's opportunity in virtual multichannel video programming distribution. 5. Arena Pharmaceuticals (ARNA) upgraded to Buy from Hold at Needham with analyst Alan Carr citing the company's "impressive results" from its Phase 2 Ulcerative Colitis study, noting that the the safety and tolerability data components are also "encouraging." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/20/18
JMPS
03/20/18
NO CHANGE
Target $79
JMPS
Outperform
Arena Pharmaceuticals price target raised to $79 from $63 at JMP Securities
JMP Securities analyst Jason Butler said Arena Pharmaceuticals' top-line results for etrasimod in ulcerative colitis meet or beat his best-case expectations and he has increased his view of the probability of success for etrasimod in UC to 75% from 50% following the report of the data. Given the higher odds he places on the success of the drug in that indication, Butler raised his price target on Arena shares to $79 from $63 and keeps an Outperform rating on the stock.
03/21/18
SBSH
03/21/18
NO CHANGE
Target $62
SBSH
Buy
Arena Pharmaceuticals price target raised to $62 from $55 at Citi
Citi analyst Joel Beatty raised his price target for Arena Pharmaceuticals to $62 after the company announced positive Phase 2 topline results for etrasimod in ulcerative colitis. The analyst increased his market penetration projections for etrasimod and maintained a 60% probability of success for the drug. He keeps a Buy rating on Arena Pharmaceuticals.
04/19/18
CANT
04/19/18
NO CHANGE
Target $65
CANT
Overweight
Arena's APD371 'another underappreciated asset,' says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner views Arena Pharmaceuticals' APD371 in Crohn's abdominal pain as "another underappreciated asset." Release of data from clinical testing is expected in Q2, but is unlikely to have a significant impact on the stock given its early nature, Tanner tells investors in a research note. He believes, however, that APD371's underlying pharmacology could positively position the drug candidate favorably versus other cannabinoid receptor modulators. The analyst raised his price target for the shares to $65 from $64 and keeps an Overweight rating on Arena Pharmaceuticals.
NOVN Novan
$2.72

0.015 (0.56%)

05/21/18
JMPS
05/21/18
NO CHANGE
JMPS
Novan Q1 results beat estimates, pipeline progressing, says JMP Securities
JMP Securities analyst Donald Ellis noted that Novan reported Q1 earnings that were ahead of JMP's estimate and the consensus estimate, and added that the company's pipeline is progressing with multiple Phase 1/Phase 2 study top-line results expected later this year. Ellis reiterated a Market Outperform rating and $14 price target on Novan shares.
SNDX Syndax
$7.23

0.46 (6.79%)

07/12/18
HCWC
07/12/18
INITIATION
Target $30
HCWC
Buy
Syndax initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White started Syndax Pharmaceuticals with a Buy rating and $30 price target. The company's company's lead pipeline candidate entinostat "could be a potent combination with other drugs," White tells investors in a research note.
05/09/18
NOMU
05/09/18
NO CHANGE
Target $22
NOMU
Buy
Syndax risk/reward positive into data, says Nomura Instinet
Nomura Instinet analyst Christopher Marai sees a positive risk/reward on Syndax Pharmaceuticals into the entinostat readout, expected in Q3. The analyst believes downside is limited on this readout, given expectations and the potential for success on the overall survival endpoint. He calls the stock "significantly undervalued" and keeps a Buy rating on Syndax with a $22 price target.
01/05/18
RILY
01/05/18
INITIATION
Target $40
RILY
Buy
Syndax initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Syndax Pharmaceuticals with a Buy rating and $40 price target. The analyst sees "highly favorable risk/reward dynamics" for the company's lead asset, entinostat, in breast cancer.
01/05/18
01/05/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Becton Dickinson (BDX) initiated with an Overweight at KeyBanc. 2. Syndax (SNDX) initiated with a Buy at B. Riley FBR. 3. Sutherland Asset Management (SLD) initiated with an Outperform at JMP Securities. 4. Nike (NKE) was assumed with a Buy at Buckingham while Under Armour (UA, UAA) was assumed with a Neutral. 5. Regulus (RGLS) initiated with an Outperform at Leerink. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
DCPH Deciphera
$39.80

0.78 (2.00%)

09/19/18
PIPR
09/19/18
NO CHANGE
Target $50
PIPR
Overweight
Piper recommends Deciphera into systemic mastocytosis data
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on shares of Deciphera Pharmaceuticals (DCPH) with a $50 price target following a deep dive into the systemic mastocytosis treatment space and the potential for DCC-2618 to play a meaningful role in the disease. The analyst continues to recommend purchase of Deciphera into the systemic mastocytosis data for DCC-2618 early next year. Given what's been presented before between Novartis' (NVS) midostaurin and Blueprint Medicines' (BPMC) avapritinib, Raymond thinks an overall response rate of greater than 50% with a continued clean safety profile should be considered a win for DCC-2618. He models for DCC-2618 systemic mastocytosis revenue of $44M, $151M, and $290M for 2023 through 2025, respectively. The analyst remains a buyer of Deciphera shares into the Q1 of 2019 data.
09/17/18
GUGG
09/17/18
INITIATION
GUGG
Guggenheim calls Array, Deciphera, ImmunoGen top biotech picks
Guggenheim initiated coverage of the biotechnology sector, initiating and assuming coverage of 17 biotechnology stocks, and saying it is bullish on the sector longer term and expects continued growth. The firm's coverage focuses on the oncology therapeutic category, with Guggenheim calling Array Biopharma (ARRY), Deciphera Pharmaceuticals (DCPH), and ImmunoGen (IMGN), which all have key catalysts coming in the first half or 2019, its top picks.
09/17/18
GUGG
09/17/18
INITIATION
Target $71
GUGG
Buy
Deciphera initiated with a Buy at Guggenheim
Target $71.
09/24/18
LEER
09/24/18
INITIATION
Target $28
LEER
Underperform
Deciphera initiated with an Underperform at Leerink
Leerink analyst Andrew Berens started Deciphera Pharmaceuticals with an Underperform rating and $28 price target.
BJ BJ's Wholesale
$28.47

-0.68 (-2.33%)

08/28/18
WELS
08/28/18
NO CHANGE
WELS
Market Perform
BJ's Wholesale quarter encouraging, but beat already expected, says Wells Fargo
Wells Fargo analyst Edward Kelly said quarterly results from BJ's Wholesale were encouraging, but that the market already expected a revenue and earnings beat. He keeps a Market Perform rating on BJ's shares, stating that the risk/reward looks fairly balanced at current levels.
09/05/18
LOOP
09/05/18
NO CHANGE
Target $35
LOOP
Buy
BJ's Wholesale price target raised to $35 from $30 at Loop Capital
Loop Capital analyst Laura Champine raised her price target on BJ's Wholesale to $35 and kept her Buy rating, saying the company is expected to increase its club opening from 2 in 2018 to 3-5 annually. The analyst also expects BJ's to grow its EBITDA by 32%, supported mainly by the 10% membership fee increase effective in January. Champine further notes that the company's merchandise same store sales have turned positive this year for the first time in at least 6 years thanks to "rationalization of private label brands, improved value messaging, and growth of ancillary product lines".
08/28/18
LOOP
08/28/18
NO CHANGE
Target $30
LOOP
Buy
BJ's price target raised to $30 after better than expected SSS at Loop Capital
Loop Capital analyst Laura Champine raised her price target on BJ's Wholesale shares to $30 from $28 after the company reported better same-store sales than she expected in Q2. She believes BJ's will grow EBITDA 31%, driven in large part by a 10% membership fee increase, and she sees merchandise SSS turning positive this year for the first time in at least six years. Champine keeps a Buy rating on BJ's shares, which are down 6.6% to $25.28 in early trading.
08/29/18
DBAB
08/29/18
NO CHANGE
DBAB
Buy
BJ's Wholesale in beginning stages of turnaround, says Deutsche Bank
Deutsche Bank analyst Mike Baker says BJ's Wholesale's Q2 results were a bit better than expected with margin and profit trends more favorable than sales, which met but didn't beat expectations. The company is in the beginning stages of a turnaround plan that is yielding some early comp momentum and improved profitability, Baker tells investors in a post-earnings research note. He keeps a Buy rating on the shares.
PETQ PetIQ
$41.07

-0.55 (-1.32%)

07/02/18
JEFF
07/02/18
NO CHANGE
Target $32
JEFF
Buy
Jefferies remains bullish on PetIQ, boosts price target to $32
Jefferies analyst Kevin Grundy raised his price target for PetIQ (PETQ) to $32 from $30 following a Walmart (WMT) store visit to a new VetIQ Petcare clinic in Lehighton, PA. The analyst sees see PetIQ's retail strategy as sensible given the high margin/return profile of the model. He believes the company's clinic rollout is on track and remains bullish on the stock with a Buy rating.
08/15/18
RHCO
08/15/18
NO CHANGE
Target $40
RHCO
Buy
PetIQ price target raised to $40 from $30 at SunTrust
SunTrust analyst William Chappell raised his price target on PetIQ to $40 and kept his Buy rating after its Q2 sales beat and raised FY18 guidance. The analyst notes that the investment story for the company now hinges on the wellness center rollout and expects to hear an update on those developments in the coming months.
04/13/18
OPCO
04/13/18
NO CHANGE
Target $28
OPCO
Outperform
PetIQ in the process of building credibility among investors, says Oppenheimer
Oppenheimer analyst Brian Nagel told investors in a research note that he came away from a recent meeting with PetIQ CEO Cord Christensen and VIP Petcare CEO Will Santana "incrementally positive." He said the company, which in the short time since its July 2017 IPO has amounted to "one of the more controversial stories among smaller cap consumer positives," is in the process of building credibility among investors and this process takes time. His Outperform rating and $28 price target reflects his intermediate to longer-term confidence in the PetIQ model and senior management, he said.
04/03/18
RHCO
04/03/18
NO CHANGE
Target $30
RHCO
Buy
PetIQ still has long growth runway, says SunTrust
Following the filing of pro forma financials of PetIQ's VIP business, SunTrust analyst William Chappell, Jr. reiterated his Buy rating and $30 price target on the shares, stating that he still sees the company having a long runway of growth ahead for both its products and services businesses.
CNP CenterPoint Energy
$27.81

-0.23 (-0.82%)

06/28/18
BOFA
06/28/18
UPGRADE
BOFA
Neutral
CenterPoint Energy upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Julien Dumoulin-Smith upgraded CenterPoint Energy to Neutral and raised its price target to $29 from $26 saying shares look attractive based on the Enable ownership stake and increasing premiums for gas and infrastructure construction peers.
09/05/18
JPMS
09/05/18
UPGRADE
Target $31
JPMS
Overweight
CenterPoint Energy upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Christopher Turnure upgraded CenterPoint Energy (CNP) to Overweight and raised his price target for the shares to $31 from $29. After modeling the impact of CenterPoint's pending acquisition of Vectren (VVC), the analyst sees an "attractive outlook for the proforma company" with 8.2% annual earnings growth through 2021 "under a conservative range of assumptions." CenterPoint trades at a 5% discount on 2019 earnings versus large cap peers despite 8%-plus growth in 2020-2021 plus a 4% yield, Turnure tells investors in a research note.
09/05/18
09/05/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Anthem (ANTM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Zack Sopcak saying he contends that the disruption in the pharmacy benefits management landscape via M&A and government-led drug pricing reform positions Anthem for underappreciated share gain and accelerated profit growth. 2. BP (BP) upgraded to Overweight from Equal Weight at Morgan Stanley. 3. GasLog (GLOG) upgraded to Buy from Hold at DNB Markets. 4. CenterPoint Energy (CNP) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Turnure saying he sees an "attractive outlook for the proforma company" with 8.2% annual earnings growth through 2021 "under a conservative range of assumptions." 5. PerkinElmer (PKI) upgraded to Equal Weight from Underweight at Barclays with analyst Jack Meehan saying he is more positive on PerkinElmer's near-term growth prospects in Diagnostics due to its recent investments. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/17/18
WELS
05/17/18
DOWNGRADE
Target $16
WELS
Market Perform
Enable Midstream downgraded to Market Perform on valuation at Wells Fargo
Wells Fargo analyst Ned Baramov downgraded Enable Midstream Partners (ENBL) to Market Perform from Outperform with an unchanged price target of $16. The analyst says "valuation and technical headwinds" move him to the sidelines. CenterPoint Energy (CNP) owns 54% of Enable Midstream's outstanding units and has indicated a multi-year goal to reduce "exposure to commodity prices through the sale of the Enable common units in the public equity markets or otherwise," the analyst points out. He believes the stock could remain range-bound until trading liquidity improves.
CTL CenturyLink
$22.90

-0.04 (-0.17%)

07/18/18
07/18/18
DOWNGRADE
Target $17

Market Perform
Adtran downgraded to Market Perform after earnings at Northland
As previously reported, Northland analyst Tim Savageaux downgraded Adtran (ADTN) to Market Perform from Outperform following the company's Q2 report and Q3 revenue guidance that met consensus, stating that he views the shares as fairly valued given that he believes the earnings power needed to support a higher share price is "still a ways off." While Adtran is "slowly but clearly diversifying away" from CenturyLink (CTL), Savageaux has lowered expectations for any snap-back at CenturyLink and sees slower than expected progress at other U.S. Tier 1 telecom companies, he tells investors. The analyst, who reduced his estimates for 2019, cut his price target on Adtran shares to $17 from $20.
06/26/18
06/26/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Micron (MU) upgraded to Neutral from Sell at UBS with analyst Timothy Arcuri saying he sees major producers taking a more anticipatory approach to DRAM supply, which will help Micron avert the downside case he previously laid out. 2. CenturyLink (CTL) upgraded to Buy from Hold at Jefferies with analyst Scott Goldman citing relatively low consumer exposure, favorable operating trends, a sustainable dividend, and improving leverage. 3. At Home Group (HOME) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Simeon Gutman stating that its new stores are ramping quicker than initially anticipated and he has increased confidence in the company's ability to generate high teens sales growth. 4. Lam Research (LRCX) upgraded to Buy from Neutral at UBS with analyst Timothy Arcuri saying NAND shipments are already down roughly 50% and he now thinks the September bar is set so low that a favorable trend can develop into 2019. 5. MercadoLibre (MELI) upgraded to Overweight from Sector Weight at KeyBanc with analyst Brad Erickson stating that he is more bullish on the company's prospects in payments after visiting several companies in the FinTech/payments and e-commerce space in Latin America. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/18
RBCM
08/16/18
NO CHANGE
Target $27
RBCM
Outperform
CenturyLink price target raised to $27 from $22 at RBC Capital
RBC Capital analyst Jonathan Atkin raised his price target on CenturyLink to $27 and kept his Outperform rating after its "solid" Q2 results and increased FY18 guidance on "stronger-than-expected synergy realization and benefits from portfolio rationalization". The analyst believes that the company's dividend yield is also safe and its operating expense synergy targets are "beatable". Atkin further notes that although CenturyLink's consumer business is "challenged", it only constitutes about 25% of its combined revenue, and its recent Level 3 Communications transaction helps its "pivot to the enterprise business" with "better underlying economics".
08/22/18
MOFT
08/22/18
DOWNGRADE
Target $19
MOFT
Sell
CenturyLink downgraded to Sell from Neutral at MoffettNathanson
MoffettNathanson analyst Nicholas Del Deo downgraded CenturyLink to Sell with a $19 price target. The shares closed yesterday up 13c to $23.98.
PBR Petrobras
$11.40

-0.105 (-0.91%)

07/11/18
LEHM
07/11/18
UPGRADE
Target $14
LEHM
Overweight
Petrobras upgraded to Overweight from Underweight at Barclays
Barclays analyst Paul Cheng double upgraded Paul Y. Cheng to Overweight from Underweight with an unchanged price target of $14. The company's steep valuation discount "more than outweighs the underlying political risk," Cheng tells investors in a research note.
07/11/18
LEHM
07/11/18
DOWNGRADE
Target $66
LEHM
Underweight
Barclays downgrades Hess to Underweight on 'steepest' group premium
Barclays analyst Paul Cheng downgraded Hess Corp. (HES) to Underweight from Equal Weight while raising his price target for the shares to $66 from $55. The analyst says his analysis indicates Hess trades at the "steepest premium" in the group. His Guyana estimate would need to move 75%-100% higher for Hess to trade in-line with large-cap Exploration and Production companies. Cheng replaced Cenovus Energy (CVE) with ConocoPhillips (COP) as his top pick following the stock's strong share performance. He also double upgraded Petrobras (PBR) Overweight from Underweight, upgraded Husky Energy (HUSKF) to Overweight and Imperial Oil (IMO) to Equal Weight. The analyst thinks Hess and Exxon Mobil (XOM) offer the least value over the next 12 months.
08/08/18
SOCG
08/08/18
NO CHANGE
Target $13.5
SOCG
Hold
Petrobras price target raised to $13.50 from $11 at Societe Generale
Societe Generale analyst John Herrlin raised his price target on Petrobras to $13.50 from $11.00 after its Q2 results were operationally better than he had expected. Herrlin, who thinks Petrobras will likely benefit from stronger Brent pricing, lower operating costs, and new FPSOs coming onstream, keeps a Hold rating on the stock.
06/11/18
06/11/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. UMC (UMC) upgraded to Market Perform from Underperform at Bernstein with analyst Mark Li saying he believes the company will deliver a better capital return. 2. Petrobras (PBR) upgraded to Market Perform from Underperform at Raymond James with analyst Pavel Molchanov saying the government's "dramatic intervention" in late May to slash diesel prices in response to a national trucker strike is largely reflected in valuation. 3. Apache (APA) upgraded to Buy from Hold at Argus with analyst Bill Selesky citing the impact of rising crude oil prices as well as the management's strategy of allocating nearly 70% of its FY18 capital spending program to production in the Permian basin. 4. Match Group (MTCH) upgraded to Buy from Hold at Jefferies with analyst Brent Thill saying a survey of 600 online daters shows many users do not wish to commingle dating with social media. 5. First Data (FDC) upgraded to Buy from Neutral at Goldman Sachs with analyst James Schneider saying despite "choppy" fundamentals, the company's revenue growth is poised to improve. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

03:40
10/15/18
10/15
03:40
10/15/18
03:40
General news
FX Action: USD-CAD has settled in the lower 1.3000s »

FX Action: USD-CAD has…

03:15
10/15/18
10/15
03:15
10/15/18
03:15
General news
FX Update: The Yen has traded moderately firmer »

FX Update: The Yen has…

BAC

Bank of America

$28.42

0.07 (0.25%)

20:25
10/14/18
10/14
20:25
10/14/18
20:25
Earnings
Notable company reporting before Monday's open »

The notable company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 24

    Oct

JPM

JPMorgan

$106.88

-1.18 (-1.09%)

19:56
10/14/18
10/14
19:56
10/14/18
19:56
Periodicals
JPMorgan's Dimon cancels plans to attend Saudi investor event, Reuters says »

JP Morgan CEO Jamie Dimon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 21

    Oct

  • 24

    Oct

  • 26

    Feb

HRS

Harris

$154.88

0.61 (0.40%)

, LLL

L3 Technologies

$195.99

0.74 (0.38%)

19:15
10/14/18
10/14
19:15
10/14/18
19:15
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

HRS

Harris

$154.88

0.61 (0.40%)

LLL

L3 Technologies

$195.99

0.74 (0.38%)

ATVI

Activision Blizzard

$77.99

4.13 (5.59%)

SNE

Sony

$55.50

-0.01 (-0.02%)

MSFT

Microsoft

$109.54

3.63 (3.43%)

TSLA

Tesla

$259.11

6.93 (2.75%)

JPM

JPMorgan

$106.88

-1.18 (-1.09%)

WFC

Wells Fargo

$52.12

0.7 (1.36%)

BAC

Bank of America

$28.42

0.07 (0.25%)

SCHW

Charles Schwab

$49.02

0.89 (1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 16

    Oct

  • 19

    Oct

  • 19

    Oct

  • 21

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 13

    Nov

  • 28

    Nov

  • 13

    Dec

  • 26

    Feb

  • 03

    Mar

  • 12

    Apr

  • 13

    Jul

  • 12

    Oct

AAPL

Apple

$222.10

7.61 (3.55%)

19:11
10/14/18
10/14
19:11
10/14/18
19:11
Periodicals
Apple buys music analytics startup Asaii, Axios reports »

Apple has acquired Asaii,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$8.65

-0.16 (-1.82%)

18:15
10/14/18
10/14
18:15
10/14/18
18:15
Periodicals
Ford chairman cancels visit to Saudi investor conference, Reuters reports »

Ford Motor Chairman Bill…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HON

Honeywell

$156.15

2.45 (1.59%)

17:16
10/14/18
10/14
17:16
10/14/18
17:16
Hot Stocks
Honeywell business jet aviation forecast projects 7,700 new aircraft deliveries »

The business jet industry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 19

    Oct

T

AT&T

$32.23

0.48 (1.51%)

, CMCSA

Comcast

$34.61

0.93 (2.76%)

16:41
10/14/18
10/14
16:41
10/14/18
16:41
Hot Stocks
Box Office Battle: 'Venom' wins domestic box office again with $35.7M »

Sony's (SNE)…

T

AT&T

$32.23

0.48 (1.51%)

CMCSA

Comcast

$34.61

0.93 (2.76%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$55.50

-0.01 (-0.02%)

FOX

21st Century Fox

$44.94

0.15 (0.33%)

FOXA

21st Century Fox

$45.36

0.23 (0.51%)

LGF.A

Lionsgate

$22.51

0.79 (3.64%)

DIS

Disney

$112.61

1.44 (1.30%)

VIAB

Viacom

$31.39

0.2 (0.64%)

VIA

Viacom

$34.46

-0.25 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

HRS

Harris

$154.88

0.61 (0.40%)

, LLL

L3 Technologies

$195.99

0.74 (0.38%)

16:33
10/14/18
10/14
16:33
10/14/18
16:33
Conference/Events
L3 Technologies and Harris to hold a joint conference call »

The companies hold a…

HRS

Harris

$154.88

0.61 (0.40%)

LLL

L3 Technologies

$195.99

0.74 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

ROK

Rockwell Automation

$172.89

2.3 (1.35%)

16:19
10/14/18
10/14
16:19
10/14/18
16:19
Hot Stocks
Harpak-ULMA, Rockwell Automation to deliver smart, connected packaging machines »

Harpak-ULMA announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVI

Activision Blizzard

$77.99

4.13 (5.59%)

, SNE

Sony

$55.50

-0.01 (-0.02%)

16:16
10/14/18
10/14
16:16
10/14/18
16:16
Hot Stocks
New Call of Duty delivers biggest launch day one digital sales for Activision »

Call of Duty: Black Ops 4…

ATVI

Activision Blizzard

$77.99

4.13 (5.59%)

SNE

Sony

$55.50

-0.01 (-0.02%)

MSFT

Microsoft

$109.54

3.63 (3.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 21

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 13

    Nov

  • 28

    Nov

  • 03

    Mar

COL

Rockwell Collins

$134.20

-0.26 (-0.19%)

, ERJ

Embraer

$19.24

-0.095 (-0.49%)

16:11
10/14/18
10/14
16:11
10/14/18
16:11
Hot Stocks
Rockwell Collins' Pro Line Fusion selected for Embraer's Praetor 500/600 jets »

Rockwell Collins'…

COL

Rockwell Collins

$134.20

-0.26 (-0.19%)

ERJ

Embraer

$19.24

-0.095 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

HON

Honeywell

$156.15

2.45 (1.59%)

, ERJ

Embraer

$19.24

-0.095 (-0.49%)

16:06
10/14/18
10/14
16:06
10/14/18
16:06
Hot Stocks
Honeywell engines to power Embraer's latest executive aircraft models »

Honeywell (HON) engines…

HON

Honeywell

$156.15

2.45 (1.59%)

ERJ

Embraer

$19.24

-0.095 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 19

    Oct

GWRE

Guidewire

$88.77

1.63 (1.87%)

16:00
10/14/18
10/14
16:00
10/14/18
16:00
Hot Stocks
Guidewire announces 2018.2 release of P&C insurance industry platform »

Guidewire announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSC

Acquired by JPM

$0.00

(0.00%)

, GS

Goldman Sachs

$213.91

0.93 (0.44%)

13:14
10/14/18
10/14
13:14
10/14/18
13:14
Periodicals
Barclays to take on Goldman with new U.S. retail current account, FT reports »

Barclays (BCS) is…

BSC

Acquired by JPM

$0.00

(0.00%)

GS

Goldman Sachs

$213.91

0.93 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

LLL

L3 Technologies

$195.99

0.74 (0.38%)

12:48
10/14/18
10/14
12:48
10/14/18
12:48
Earnings
L3 Technologies raises FY18 adjusted EPS view to $10.20-$10.30 from $9.80-$10.00 »

FY18 consensus $10.05.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

LLL

L3 Technologies

$195.99

0.74 (0.38%)

12:42
10/14/18
10/14
12:42
10/14/18
12:42
Earnings
L3 Technologies reports preliminary Q3 adjusted EPS $2.85, consensus $2.41 »

Reports preliminary Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

HRS

Harris

$154.88

0.61 (0.40%)

12:28
10/14/18
10/14
12:28
10/14/18
12:28
Earnings
Harris raises FY19 cont ops EPS $7.80-$7.90, consensus $7.84 »

Sees FY19 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

HRS

Harris

$154.88

0.61 (0.40%)

12:24
10/14/18
10/14
12:24
10/14/18
12:24
Earnings
Harris reports Q1 adjusted EPS $1.78, consensus $1.71 »

Reports Q1 revenue $1.5B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

HRS

Harris

$154.88

0.61 (0.40%)

, LLL

L3 Technologies

$195.99

0.74 (0.38%)

12:18
10/14/18
10/14
12:18
10/14/18
12:18
Hot Stocks
Harris, L3 Technologies to combine in merger of equals »

Harris Corporation (HRS)…

HRS

Harris

$154.88

0.61 (0.40%)

LLL

L3 Technologies

$195.99

0.74 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

LOACU

Longevity Acquisition Corporation

$10.24

(0.00%)

12:11
10/14/18
10/14
12:11
10/14/18
12:11
Hot Stocks
Longevity Acquisition announces separate trading of ordinary shares, rights »

Longevity Acquisition…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRS

Harris

$154.88

0.61 (0.40%)

, LLL

L3 Technologies

$195.99

0.74 (0.38%)

08:10
10/14/18
10/14
08:10
10/14/18
08:10
Periodicals
Harris, L3 Technologies near agreement to merge, WSJ reports »

Harris Corporation (HRS)…

HRS

Harris

$154.88

0.61 (0.40%)

LLL

L3 Technologies

$195.99

0.74 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

SCHW

Charles Schwab

$49.02

0.89 (1.85%)

19:36
10/13/18
10/13
19:36
10/13/18
19:36
Conference/Events
Charles Schwab to host conference call »

Fall business update…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Oct

  • 19

    Oct

FDX

FedEx

$220.97

3.54 (1.63%)

16:46
10/13/18
10/13
16:46
10/13/18
16:46
Conference/Events
FedEx management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.